UROLIFT MA00207-01 Transprostatic Implant System User Guide
- June 4, 2024
- UROLIFT
Table of Contents
UROLIFT MA00207-01 Transprostatic Implant System
UroLift® System and Indications
The UroLift® transprostatic implant system retracts prostate tissue away from the urethra without cutting, heating or removing prostate tissue. This FDA cleared device is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH), including lateral and median lobe hyperplasia, in men age 45 or older.
UroLift® System Procedure
The UroLift® System is comprised of a cystoscopic delivery device which the
physician uses to deploy permanent, individually tailored transprostatic
implants to retract the obstructing prostatic lobes. Although it is predicated
on the patient’s anatomy and prostate size, the number of implants used in a
procedure is determined by the treating physician.
Cystoscopy is conducted to assess the urethral condition, assess the condition
of the bladder, and plan the placement of the implants. At the time of the
procedure, a cystoscopy sheath is advanced into the bladder, and the telescope
bridge is replaced with the UroLift System implant delivery device.
Under endoscopic guidance, the physician determines the precise location to compress the obstructing prostatic lobe and deploys the transprostatic implant. Each implant is assembled and tailored in situ as it is delivered. After the appropriate number of implants are placed, the physician removes the UroLift System delivery device and sheath, leaving retracted lateral prostatic lobes. The exact number of transprostatic implants required is determined by a trained physician and can vary depending on the size and shape of the prostatic lobes. Typically, the physician conducts a final cystoscopy to assess the result of creating a continuously open channel through the anterior aspect of the prostatic urethra.
- The UroLift® System is conducted cystoscopically through the urethra to access the obstructing lobes of the enlarged prostate.
- Permanent implants are delivered transurethrally through the prostate tissue to open the urethra lumen.
- Based on the unique characteristics of the prostate, every implant is assembled and tailored in situ as it is delivered.
- The implants hold the prostatic urethra in a less obstructed configuration, thereby mitigating BPH symptoms.
UroLift® System Reimbursement Support
NeoTract | Teleflex Incorporated has developed this Billing Guide to help
support your efforts throughout the reimbursement process for the prostatic
urethral lift procedure using the UroLift® System. Additional resources can be
found at
www.UroLift.com/physicians/reimbursement
or through the NeoTract Reimbursement Team at 844.516.5966 or by email at
UroLiftreimbursement@teleflex.com.
Billing UroLift® System Procedures
Diagnosis Coding
It is always the responsibility of the provider to verify codes and code to
the highest level of specificity. Because the
UroLift® System is indicated for lower urinary tract symptoms associated with
BPH, the most common diagnosis code is: Table 1
ICD-10 Diagnosis Coding
Code| Description
N40.1| Benign prostatic hyperplasia with lower urinary tract symptoms (LUTS)
Prior Authorization
Many insurers require authorization prior to the physician treating the
patient. As such, prior authorization is recommended for all non-Medicare
prostatic urethral lift procedures including Managed Care Medicare (aka
Medicare Advantage). Like many other procedures and tests, some insurers have
established medical necessity criteria for the UroLift System treatment. Your
UroLift System sales representative or the reimbursement support team can
provide a summary by insurer of the criteria we are aware of. To further
assist with the prior authorization process, a sample letter of medical
necessity can be found online under the Reimbursement tab of the UroLift
System website at
www.UroLift.com/physicians/reimbursement.
Some insurers do not require prior authorization for outpatient procedures. If
that is what you are told by an insurer specific to the UroLift System
procedure, please request a voluntary, written authorization from insurer
prior to proceeding with the case. Retain the authorization in the patient
chart for future reference as needed.
UroLift® System Procedure Coding
Medicare: Procedural HCPCS codes are used to describe the prostatic urethral
lift procedure, including implants, in the hospital outpatient settings.
Allowed amounts may vary geographically and are inclusive of the permanent
transprostatic implants. One or the other procedural HCPCS codes will be used
depending on the number of permanent implants delivered.
HCPCS codes C9739 and C9740 map to APCs 5375 and 5376 respectively. Please see
Table 2 below for more information on the nationally unadjusted allowed
amounts for the hospital outpatient site of service. In addition to Medicare,
some commercial insurers may recognize the procedural HCPCS codes C9739 and
C9740 in the hospital outpatient setting. Some insurers, however, may choose
to have CPT® codes 52441 and 52442 used to report the prostatic urethral lift
procedure in these sites of service. Please verify with your non-Medicare
insurer their preference for reporting of this procedure. Table 2
Facility: Medicare*| Hospital Outpatient| |
---|---|---|---
HCPCS| Description| APC| APC Nat’l’ Unadjusted Allowed Amount**| SI1
C9739| Cystourethroscopy, with insertion of transprostatic implant; 1 to 3
implants| 5375| $4,506| J1
C9740| Cystourethroscopy, with insertion of transprostatic implant; 4 or more
implants| 5376| $8,429| J1
Device Code – Hospital Outpatient Only
HCPCS| Description
L8699| Prosthetic implant, not otherwise specified (each implant)
Department of Health and Human Services, Centers for Medicare & Medicaid
Services. CMS – 1753 – FC: Hospital Outpatient Prospective Payment and
Ambulatory Surgical Center Payment Systems Final Rule with Comment Period and
CY2022 payment rates.
Rates referenced in this guide do not reflect sequestration adjustments which
are automatic reductions in federal spending that will result in a 2% across-
the-board reduction to all Medicare rates as of April 1,2013. Quoted rates
also do not reflect payment adjustments related to quality of and/or
meaningful use.
CPT® codes and descriptions are copyright 2021 American Medical Association
(AMA). All rights reserved. CPT® is a registered trademark of the American
Medical Association. Hospital Outpatient Status indicators: J1: Comprehensive
APC, Payment for all adjunctive services reported on the same claim is
packaged into payment for the primary service.
Medicare designated both UroLift System HCPCS codes device intensive which
requires that hospital claims not only
report the HCPCS procedure code, but also a HCPCS device code for each implant
delivered. Currently CMS/Medicare recommends that L8699 be used to report and
price each implant delivered. Reporting HCPCS code L8699 will not receive
additional Medicare reimbursement, but it will help ensure claims are not
rejected for being incomplete. Reporting L8699 with appropriate charges based
on your unique CCR will also help to protect future APC assignment and rate
setting. Commercial insurers may process L8699 separately for payment.
Non-Medicare: Some non-Medicare insurers do not recognize HCPCS codes
developed by CMS. It is recommended that you verify with each insurer their
coding preference for outpatient facility claims. If CPT codes are
recommended, CPT code 52441 will always be listed only once and add-on CPT
code 52442 may require multiple units based on the number of additional
implants used. Please see Table 3 below for more information. Non-Medicare
insurer fee schedules are typically proprietary and will vary by insurer and
product. Consider requesting your fee schedule amounts for either HCPCS C9739
and C9740 or, if preferred by the insurer, CPT code 52441 and 52442 from each
insurer.
Table 3
Facility: Alternative Coding May Be Required by Some Non-Medicare and Medicare
Advantage Plans| Hospital
---|---
CPT®| Description| APC
52441| Cystourethroscopy, with insertion of permanent adjustable
transprostatic implant; single implant| Insurer priced
+52442| Each additional permanent adjustable transprostatic implant (List
separately in addition to code for primary procedure)| Insurer priced
Revenue Codes
Hospital billing staff should confirm the appropriate revenue codes to use at
their facility. The following revenue codes may be appropriate for reporting
components of the UroLift® System procedure:
Table 4
0278 | Medical/surgical supplies and devices – other implants |
---|---|
0360 | Operating room services – general |
0361 | Operating room services – minor surgery |
0490 | Ambulatory surgical care – general |
0510 | Clinic – general classification |
0519 | Clinic – other clinic |
Sample UB-04 Claim Forms
For Medicare Outpatient Billing
When Required for Non-Medicare Outpatient Billing
Filing Claims & Appeals
Claims & Appeals Information
Medicare and commercial insurers may request additional documentation before
or during processing claims. Providing appropriate documentation of medical
necessity upon request may help to avoid unnecessary payment delays and
denials. A sample letter addressing medical necessity can be found online
under the Reimbursement tab of the UroLift® System website at
www.UroLift.com/physicians/reimbursement.
In the event of a denied, or what appears to be underpaid claim, various
sample appeal letters, letters of support
from specialty societies like the American Urological Association, Sexual
Medicine Society, SUFU, and link to the AUA Clinical Guidelines
[www.auanet.org/guidelines/benign-prostatic-
hyperplasia-(bph)-guideline] on the Surgical Management of BPH
are available online under the Reimbursement tab of the UroLift System website
at
www.UroLift.com/physicians/reimbursement.
In addition, please review the checklists below for guidance on filing claims
and appealing denied claims. It will be important to consider these tips in
preparing and processing UroLift System procedure claims and appeals.
Checklist for Claim Submission
- Review the Payor Coverage Policy Lookup Tool to verify your state’s coverage at www.UroLift.com/physicians/reimbursement under the physician’s tab
- File the claim within the timeline for each insurer
- If appropriate, include prior authorization or precertification verification from insurer
- Select the appropriate CPT or HCPCS code depending on the procedure, location and number of implants
- Code diagnosis, codes to the highest level of specificity
- Always maintain thorough documentation supporting the medical necessity of the prostatic urethral lift procedure
- Consider keeping a copy of the product invoice in the patient’s chart in the event it is requested by an insurer
- For reimbursement questions, contact the NeoTract Reimbursement Team at 844.516.5966
Checklist for Appealing Denied Claims
- Verify the most appropriate Dx code was used
- Use an accurate description of services
- Include a statement of medical necessity (see a sample letter of medical necessity online at www.UroLift.com/physicians/reimbursement)
- Refer to the sample appeal letters online at www.UroLift.com/physicians/reimbursement for more information
- Always reference and include all original claim information and correspondence from the insurer
- Follow the insurer’s appeal process paying special attention to filing timelines
- Follow up on the appeal in a timely fashion
- For reimbursement questions, contact the NeoTract
- Follow up on the appeal in a timely fashion
- For reimbursement questions, contact the NeoTract Reimbursement Team at 844.516.5966
Published January 2022
CPT® codes copyright and ® American Medical Association
THE UROLIFT® SYSTEM REIMBURSEMENT SUPPORT TEAM 844.516.5966
uroliftreimbursement@teleflex.com
Pleasanton, CA 94588 FDA: 3015181082 www.UroLift.com